USPTO Examiner RICCI CRAIG D - Art Unit 1611

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19060293URSOLIC ACID MORPHOLINE SALTFebruary 2025June 2025Allow310YesNo
18910781URSOLIC ACID MORPHOLINE AND DIETHANOLAMINE SALTSOctober 2024November 2024Allow100YesNo
18904951Constrained Ionizable Cationic Lipids and Lipid NanoparticlesOctober 2024May 2025Allow801NoNo
18652849NOVEL POTASSIUM CHANNEL INHIBITORSMay 2024April 2025Allow1201YesNo
18635375PYRAZINO[1',2':1,5]PYRAZOLO[4,3-B][1,6]NAPHTHYRIDINES COMPOUNDS AS CK2 INHIBITORSApril 2024July 2024Allow300YesNo
18594338Blarcamesine co-crystals for the manufacture of pharmaceutical dosage formMarch 2024April 2025Allow1401YesNo
184379034,5-BIS(4-CHLOROPHENYL)-1-HEXYL-2-(3,4-DIMETHOXYPHENYL)-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUNDFebruary 2024April 2024Allow200YesNo
184313716'-(2-BROMOPHENYL)-2'-ETHOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS AN ANTIOXIDANT COMPOUNDFebruary 2024June 2024Allow500YesNo
18413352NON-POLYAMINE BASED POLYAMINE TRANSPORT INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN CANCERSJanuary 2024March 2025Allow1401YesNo
18542159PYRAZINO[1',2':1,5]PYRAZOLO[4,3-B][1,6]NAPHTHYRIDINES COMPOUNDS AS CK2 INHIBITORSDecember 2023March 2024Allow300YesNo
18527967BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOFDecember 2023May 2025Abandon1701NoNo
185097422-(1-(2-HYDROXYPROPYL)-4,5-DIPHENYL-1H-IMIDAZOL-2-YL)PYRIDINE AS AN ANTICANCER COMPOUNDNovember 2023January 2024Allow200YesNo
183881034,5-BIS(4-CHLOROPHENYL)-1-HEXYL-2-(3,4-DIMETHOXYPHENYL)-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUNDNovember 2023January 2024Allow200YesNo
183865496'-(2-BROMOPHENYL)-2'-ETHOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS AN ANTIOXIDANT COMPOUNDNovember 2023January 2024Allow200YesNo
183859896'-(3-BROMOPHENYL)-2'-METHOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS AN ANTIOXIDANT COMPOUNDNovember 2023January 2024Allow300YesNo
184989896'-(4-BROMOPHENYL)-2'-ETHOXY-3,4'-BIPYRIDINE-3'-CARBONITRILE AS AN ANTIOXIDANTOctober 2023January 2024Allow200YesNo
184930171-Methyl-4-[(4-Phenylphenyl)Sulfonylmethyl]Cyclohexyanol And 1-Methyl-4-[[4-(2-Pyridyl)Phenyl]Sulfonylmethyl]Cyclohexanol Compounds and Their Therapeutic UseOctober 2023December 2024Allow1301NoNo
18484798COMPOSITIONS FOR THE TREATMENT OF BLEPHARITISOctober 2023May 2025Abandon2001NoNo
184843844-(4-BROMOPHENYL)-2- ALKYLOXY-6-(2-OXO-2H-1-BENZOPYRAN-3-YL)PYRIDINE-3-CARBONITRILE AS ANTIMICROBIAL COMPOUNDSOctober 2023January 2024Allow300YesNo
183723957-(4-((5-(4-CHLOROBENZYLIDENEAMINO)-2-THIOXO-1,3,4-THIADIAZOL-3(2H)-YL)METHYL)IPERAZIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY COMPOUNDSeptember 2023November 2023Allow200YesNo
18367760Compounds and Methods for Inhibiting CYP26 EnzymesSeptember 2023January 2025Allow1601YesNo
182421525-SUBSTITUTED AMINOPYRIMIDO[6',1':2,3]IMIDAZO[4,5-C][1,6]NAPHTHYRIDINE COMPOUNDS AS CK2 INHIBITORSSeptember 2023December 2023Allow301YesNo
182384252-(1-(2-HYDROXYPROPYL)-4,5-DIPHENYL-1H-IMIDAZOL-2-YL)PYRIDINE AS AN ANTICANCER COMPOUNDAugust 2023July 2024Abandon1120YesNo
18361275STEROIDS AND PROTEIN-CONJUGATES THEREOFJuly 2023February 2025Allow1811YesNo
18225925Blarcamesine co-crystals for the manufacture of pharmaceutical dosage formJuly 2023February 2024Allow701YesNo
18225236SOLID FORMS OF 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL)-3,5-DIHYDRO-2H-PYRIDO[3,4-F][1,4]OXAZEPINE-9-CARBONITRILEJuly 2023July 2024Abandon1210YesNo
18355790METHODS OF TREATING FIBROSISJuly 2023September 2024Allow1400NoNo
18215077SELECTIVE 5-LO INHIBITORS FOR THE TREATMENT OF BRONCHIAL ASTHMAJune 2023August 2023Allow200YesNo
18334611BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOFJune 2023April 2024Allow1012YesNo
18136777INTRAVENOUS BACLOFEN FORMULATIONS AND TREATMENT METHODSApril 2023January 2025Allow2110YesNo
18295009BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORSApril 2023December 2024Allow2010NoNo
18029842Crystalline Forms of a Pharmaceutical CompoundMarch 2023June 2024Allow1411YesNo
18128828SINGLE PROTEIN-ENCAPSULATED PHARMACEUTICS FOR ENHANCING THERAPEUTIC EFFECTSMarch 2023January 2025Allow2211YesNo
18120757COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING DISEASESMarch 2023February 2025Allow2311NoNo
18116593Kr�ppel-Like Factor 15 (KLF15) Small Molecule Agonists in Kidney DiseaseMarch 2023December 2024Allow2111NoNo
18175030Fused Pentacyclic Imidazole Derivatives as Modulators of TNF ActivityFebruary 2023October 2024Abandon2001NoNo
18168155OPIOID RECEPTOR MODULATORSFebruary 2023August 2024Allow1801YesNo
18102474THERAPEUTIC METAL COMPLEXES AND LIGANDS AND METHODS OF MAKING AND USING THE SAMEJanuary 2023February 2025Allow2521YesNo
18094502Solid Forms of Substituted Benzoxaborole and Compositions ThereofJanuary 2023May 2024Allow1600YesNo
18094113SELECTIVE 5-LO INHIBITORS FOR THE TREATMENT OF BRONCHIAL ASTHMAJanuary 2023March 2023Allow300YesNo
17992457SOLID FORMS OF AN S1P-RECEPTOR MODULATORNovember 2022December 2024Abandon2501NoNo
17978818A2-73 CRYSTALLINE POLYMORPH COMPOSITIONS OF MATTER AND METHODS OF USE THEREOFNovember 2022August 2024Allow2101YesNo
17970577MEDICAMENT FOR TREATING HYPERTENSIONOctober 2022January 2025Abandon2720NoNo
17969235FOOD INGREDIENTS FROM STEVIA REBAUDIANAOctober 2022January 2025Abandon2710NoNo
17935911DEPOT ADMINISTRATION OF ILOPERIDONESeptember 2022August 2024Abandon2210NoNo
17907290ANTIMICROBIAL TUBULAR CONDUITSSeptember 2022June 2025Allow3200NoNo
17943652NUTRITIONAL COMPOSITIONS AND INFANT FORMULA FOR PROMOTING DE NOVO MYEALINATIONSeptember 2022May 2025Allow3211YesNo
17930218USE OF COMBINED INHALANT CANNABINOID THERAPY IN THE TREATMENT OF MIGRAINESeptember 2022March 2024Abandon1801NoNo
17891351CYCLOSPORINE COMPOSITIONS AND METHODS OF USEAugust 2022May 2025Allow3300YesNo
17884403LOW DOSE PRODUCT AND METHOD FOR TREATING DIARRHEAAugust 2022May 2025Abandon3311NoNo
17810805COMPOSITIONS OF BIOACTIVE FULVATE FRACTIONS AND USES THEREOFJuly 2022May 2025Abandon3511NoNo
17855501CARBONIC ANHYDRASE ENZYMES FOR REGULATING MAST CELL HEMATOPOIESIS AND TYPE 2 INFLAMMATIONJune 2022November 2024Allow2911YesNo
17853367USE OF CANNABIDIOL IN THE TREATMENT OF EPILEPSYJune 2022December 2024Abandon3011NoNo
17850198SOLID POLYMORPHS OF A FLNA-BINDING COMPOUND AND ITS HYDROCHLORIDE SALTSJune 2022April 2024Allow2101YesNo
17842415Protease Inhibitors for Treatment of Coronavirus InfectionsJune 2022November 2024Abandon2921NoNo
17834127HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTSJune 2022November 2024Allow2911NoNo
17833105PHARMACEUTICAL COMPOSITION FOR TREATING MIGRAINEJune 2022July 2024Allow2501YesNo
17831863PHARMACEUTICAL COMPOSITION COMPRISING PDE9 INHIBITORJune 2022April 2025Abandon3421NoNo
17828412SINGLE-INJECTION METHODS AND FORMULATIONS TO INDUCE AND CONTROL MULTIPLE OVARIAN FOLLICLES IN BOVINE, CAPRINE, OVINE, CAMELID AND OTHER FEMALE ANIMALSMay 2022February 2024Allow2101YesNo
17737656HETEROCYCLIC COMPOUNDSMay 2022April 2024Abandon2401NoNo
177194303H,4H,5H,6H,7H-PYRIMIDO[4,5-B][1,4]OXAZINE-4,6-DIONE DERIVATIVES AS TRPA1 INHIBITORSApril 2022May 2023Allow1300NoNo
17715009NOVEL ENTERIC COMBINATION THERAPYApril 2022February 2023Allow1020YesNo
17714030OPIOID RECEPTOR MODULATORSApril 2022November 2022Allow711YesNo
17682711DYE ENHANCED VISUALIZATION OF CATARACT SURGERYFebruary 2022July 2024Abandon2911NoNo
17682624METHODS OF TREATING HEPATIC ENCEPHALOPATHYFebruary 2022April 2024Allow2610NoNo
17681368Herbal Formulation for the Prevention and Management of COVID-19 by Regulating Immunomodulatory PropertiesFebruary 2022July 2024Abandon2901NoNo
17680782HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USEFebruary 2022May 2024Abandon2701NoNo
17679796POROUS POLYMER SCAFFOLD AND METHODS THEREOFFebruary 2022June 2024Abandon2801NoNo
17670733Oral Cannabinoid FormulationsFebruary 2022June 2025Allow4021YesNo
17591075COMPOSITIONS COMPRISING SOLVENT, A MONOALCOHOL, GLYCERIN, AND THICKENERFebruary 2022May 2024Allow2711YesNo
17588816HETEROCYCLIC COMPOUNDSJanuary 2022February 2024Abandon2510NoNo
17630846ADENOSINE RECEPTOR ANTAGONISTJanuary 2022May 2025Allow4001YesNo
17584951ORAL PREPARATION OF GLUCOKINASE ACTIVATOR AND PREPARATION METHOD THEREFORJanuary 2022May 2024Abandon2811NoNo
17583841PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAMEJanuary 2022February 2025Allow3600YesNo
17579482EXTRACELLULAR VESICLE COMPOSITIONS AND METHODS OF USE THEREOFJanuary 2022March 2024Abandon2601NoNo
17570851LIPOPHILIC THIRD GENERATION RETINOIDJanuary 2022August 2024Allow3121YesNo
17571018CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAMEJanuary 2022April 2024Allow2811NoNo
17569182TANNIN-BASED ANTIPROLIFERATIVE PHARMACEUTICALJanuary 2022April 2025Allow3941YesNo
17558877EBNA1 Inhibitors and Their Method of UseDecember 2021November 2024Allow3521NoNo
17558900NEUROPROTECTIVE PHYLLANTHUS EMBLICA-CONTAINING COMPOSITIONS AND METHODSDecember 2021December 2023Abandon2301NoNo
17552816HETEROCYCLIC COMPOUNDSDecember 2021March 2024Abandon2711NoNo
17551791Increasing Drug Bioavailability In Naltrexone TherapyDecember 2021November 2023Abandon2320YesNo
17615624COMPOSITION COMPRISING N6-BENZYLAMINOPURINE FOR CONTROLLING PLANT GROWTH, PREPARATION METHOD THEREFOR, AND USE THEREOFDecember 2021June 2025Allow4211YesNo
17535911ANTIVIRAL, ANTIBACTERIAL AND/OR ANTI FUNGAL COMPOSITIONS, APPLICATIONS AND THERAPYNovember 2021February 2024Abandon2601NoNo
17455652METHODS OF TREATING HEAVY MENSTRUAL BLEEDINGNovember 2021September 2022Allow1021YesNo
17455033METHOD FOR PREVENTING OR TREATING GASTROESOPHAGEAL REFLUX DISEASE WITH FIBERS FORMED OF �-1-4-GLUCANNovember 2021November 2024Allow3621YesNo
17611158CRYSTALLINE FORM OF SOFPIRONIUM BROMIDE AND PREPARATION METHOD THEREOFNovember 2021May 2025Abandon4201NoNo
17524169HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTSNovember 2021March 2022Allow401NoNo
17453056NUTRITIONAL COMPOSITION FOR GLUCOSE SUPPORTNovember 2021June 2024Abandon3211NoNo
17505394Nutraceutical Reduction Prevention and/or Reversion of Multiple SclerosisOctober 2021March 2024Abandon2911NoNo
17498722Composition for Preventing and Treating Heart Dysfunction and its Application ThereofOctober 2021December 2023Abandon2610YesNo
17450377Treatment of Hearing Loss by Inhibition of Casein Kinase 1October 2021June 2025Allow4401YesNo
17594086REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSISOctober 2021December 2024Allow3831NoNo
17489406BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOFSeptember 2021May 2023Allow2031YesNo
17486197PH-SENSITIVE AND BIOREDUCIBLE POLYMER-VIRUS COMPLEX FOR CANCER TREATMENTSeptember 2021December 2023Allow2610YesNo
17448635SUBSTITUTED THIOPHENE OLIGOMERS AND POLYMERSSeptember 2021September 2023Allow2421YesNo
17437447NOVEL POTASSIUM CHANNEL INHIBITORSSeptember 2021February 2024Allow2901YesNo
17470487METHOD FOR TREATING ARTHRITIS BY USING STEM CELL PREPARATION AND METHOD FOR PREPARING STEM CELL PREPARATIONSeptember 2021March 2025Allow4221YesNo
17447090APPLICATION OF ATRACTYLODES LANCEOLATA ESSENTIAL OILSeptember 2021March 2024Abandon3010NoNo
17467772COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING DISEASESSeptember 2021July 2023Abandon2201NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner RICCI, CRAIG D.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
5
Examiner Affirmed
3
(60.0%)
Examiner Reversed
2
(40.0%)
Reversal Percentile
59.9%
Higher than average

What This Means

With a 40.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
40
Allowed After Appeal Filing
12
(30.0%)
Not Allowed After Appeal Filing
28
(70.0%)
Filing Benefit Percentile
42.3%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 30.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner RICCI, CRAIG D - Prosecution Strategy Guide

Executive Summary

Examiner RICCI, CRAIG D works in Art Unit 1611 and has examined 557 patent applications in our dataset. With an allowance rate of 66.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 27 months.

Allowance Patterns

Examiner RICCI, CRAIG D's allowance rate of 66.2% places them in the 19% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by RICCI, CRAIG D receive 1.92 office actions before reaching final disposition. This places the examiner in the 61% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by RICCI, CRAIG D is 27 months. This places the examiner in the 55% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +50.2% benefit to allowance rate for applications examined by RICCI, CRAIG D. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 25.1% of applications are subsequently allowed. This success rate is in the 29% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 13.6% of cases where such amendments are filed. This entry rate is in the 8% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 88.9% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 65% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 81.5% of appeals filed. This is in the 71% percentile among all examiners. Of these withdrawals, 54.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 45.5% are granted (fully or in part). This grant rate is in the 51% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 1.6% of allowed cases (in the 74% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.